Biogen (BIIB) is a publicly traded Healthcare sector company. As of July 5, 2026, BIIB trades at $216.12 with a market cap of $31.91B and a P/E ratio of 23.11. BIIB moved +3.02% today. Year to date, BIIB is +22.52%; over the trailing twelve months it is +62.26%. Its 52-week range spans $110.04 to $219.72. Analyst consensus is buy with an average price target of $224.50. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biogen halts Apellis Phase II trials and cuts R&D after $5.6bn buyout: Biogen will halt most Apellis research programmes and suspend Phase II Empaveli trials in delayed graft function and FSGS after its $5.6bn takeover. It will cut research staff and concentrate on its recruiting Phase II Syfovre plus APL-3007 trial and pegcetacoplan franchise forecast to earn $785m by 2032.
| Metric | Value |
|---|---|
| Price | $216.12 |
| Market Cap | $31.91B |
| P/E Ratio | 23.11 |
| EPS | $9.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $219.72 |
| 52-Week Low | $110.04 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $9.94B |
| Net Income | $1.37B |
| Gross Margin | 75.49% |
26 analysts cover BIIB: 0 strong buy, 17 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $224.50.